Good morning :)
Max Healthcare Institute Ltd

Max Healthcare Institute Ltd

MAXHEALTH Share Price

NSE
1,094.750.39% (+4.30)
High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

With a market cap of ₹1,06,545 cr, stock is ranked 106

Stock is 2.02x as volatile as Nifty

MAXHEALTH Stock Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is underpriced but is in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

With a market cap of ₹1,06,545 cr, stock is ranked 106

Stock is 2.02x as volatile as Nifty

MAXHEALTH Performance & Key Metrics

MAXHEALTH Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
73.8711.360.18%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
41.316.170.56%

MAXHEALTH Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 
83%
Analysts have suggested that investors can buy this stock

from 23 analysts

Price Upside

Earnings Growth

Rev. Growth

See Detailed Forecast

MAXHEALTH Company Profile

Max Healthcare is provider of home health care services including Patient Care, Healthcare Services, and Hospitals.

Investor Presentation

View older View older 

May 26, 2026

PDF
View Older Presentations

MAXHEALTH Similar Stocks (Peers)

Compare with peers Compare with peers 

MAXHEALTH Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
62.87
62.87
1Y Return
21.11%
21.11%
Buy Reco %
86.21
86.21
PE Ratio
69.78
69.78
1Y Return
28.72%
28.72%
Buy Reco %
84.21
84.21
PE Ratio
107.79
107.79
1Y Return
41.65%
41.65%
Buy Reco %
100.00
100.00
PE Ratio
47.36
47.36
1Y Return
0.26%
0.26%
Buy Reco %
85.71
85.71
PE Ratio
61.21
61.21
1Y Return
8.84%
8.84%
Buy Reco %
88.24
88.24
Compare with Peers

MAXHEALTH Sentiment Analysis

MAXHEALTH Sentiment Analysis

New
Crisp summary & key insights to decode earnings calls instantly

MAXHEALTH Stock Summary · May 2026

Management framed the quarter as one of constructive operational momentum driven by phased capacity rollouts and disciplined commissioning, underpinned by FY26 network gross revenue of INR 10,538 crore and operating EBITDA of INR 2,638 crore (26.2% margin). They emphasized rapid brownfield activation and staged greenfield builds—more than 20% additional brownfield capacity across Mohali, Nanavati and Max Smart to be operationalized in the next 2–3 months, roughly 100 brownfield beds already EBITDA‑positive, a 500‑bed Gurugram project with an initial ~200 beds targeted for year‑end, and a Board‑approved INR 1,400 crore, 700‑bed Lucknow program on a multi‑year phased timeline—while stressing beds will only be opened where demand exists and clinical/non‑clinical staff have been onboarded to capture operating leverage. Management also acknowledged tension from a CGHS chemotherapy pricing change and drug withdrawals that trimmed oncology OBDs ~5–6% and lowered oncology’s inpatient share to ~21%, and a temporary 9% ALOS rise that reduced ARPOB; they quantified a net CGHS benefit of INR 140 crore (INR 100–110 crore realized, ~INR 30–40 crore outstanding) with no definitive reversal timeline. Near term, additional brownfield beds will be activated over coming quarters, Gurugram commissioning is moved to year‑end after a two‑month delay, and cash generation and lower net debt (INR 1,908 crore) are being used to fund expansion while margins absorb short‑term lumpiness.

MAXHEALTH Stock Growth Drivers
MAXHEALTH Stock Growth Drivers
5
  • Accelerated capacity expansion and faster project execution

    The company is materially increasing bed capacity through both brownfield and greenfield projects and demonstrating

  • Strong financial performance and robust cash generation with deleveraging

    Financial results show consistent top‑line and margin strength alongside meaningful cash generation and balance‑sheet improvement.

MAXHEALTH Stock Challenges
MAXHEALTH Stock Challenges
5
  • Oncology drug pricing change and chemotherapy discontinuations driving material revenue and margin hit

    A sectoral pricing shift and related institutional MoU conditionalities forced hospitals to supply certain chemotherapy

  • Operational and regulatory disruptions causing project delays and execution risk

    Several development projects have experienced multi‑month slippages and episodic stoppages driven by non‑routine operational and

MAXHEALTH Forecast

MAXHEALTH Forecasts

Price

Revenue

Earnings

MAXHEALTH

MAXHEALTH

Income

Balance Sheet

Cash Flow

MAXHEALTH Income Statement

MAXHEALTH Income Statement

Loading...

Quarterdec 2023mar 2024jun 2024sep 2024dec 2024mar 2025jun 2025sep 2025dec 2025mar 2026
Total Revenue1,380.991,468.151,577.631,748.301,901.611,956.662,064.082,168.372,112.902,190.72
Operating & Other expensessubtract949.111,041.371,155.541,256.921,442.811,398.121,504.661,560.321,577.421,536.46
Depreciation/Amortizationsubtract60.9670.3276.9084.1597.54100.83104.14108.10111.27123.02
Interest & Other Itemssubtract11.2420.7323.8833.5452.3955.2154.8553.9259.6766.66
Taxes & Other Itemssubtract70.3484.1985.0491.8870.0783.5092.46-45.2763.62122.36
EPS2.982.592.432.902.463.283.175.053.103.52

MAXHEALTH Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2026FY 2026

Annual Report Pending

Investor Presentation

May 26PDF
Feb 20PDF
Feb 7PDF
+3 more
FY 2025FY 2025

Annual report

PDF

Investor Presentation

May 31PDF
FY 2024FY 2024

Annual report

PDF

Investor Presentation

Aug 21PDF
FY 2023FY 2023

Annual report

PDF

Investor Presentation

Feb 2PDF
Nov 8PDF
FY 2022FY 2022

Annual report

PDF
FY 2021FY 2021

Annual report

PDF
FY 2020FY 2020

Annual report

PDF
 

MAXHEALTH Stock Peers

MAXHEALTH Past Performance & Peer Comparison

MAXHEALTH Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CareHospitals & Diagnostic Centres

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Max Healthcare Institute Ltd73.8711.360.18%
Apollo Hospitals Enterprise Ltd62.8711.000.24%
Fortis Healthcare Ltd69.787.930.10%
Aster DM Healthcare Ltd107.7911.460.36%

MAXHEALTH Stock Price Comparison

Compare MAXHEALTH with any stock or ETF
Compare MAXHEALTH with any stock or ETF
MAXHEALTH
Loading...

MAXHEALTH Holdings

MAXHEALTH Shareholdings

MAXHEALTH Promoter Holdings Trend

MAXHEALTH Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

MAXHEALTH Institutional Holdings Trend

MAXHEALTH Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Decreased Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has decreased by 5.17%

Tickertape Separator

MAXHEALTH Shareholding Pattern

MAXHEALTH Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding23.71%16.30%10.01%45.39%4.58%

Jun 2025

Sep 2025

Dec 2025

Mar 2026

MAXHEALTH Shareholding History

MAXHEALTH Shareholding History

Dec '24MarJunSepDec '25Mar56.93%54.74%54.76%51.80%50.55%45.39%

Mutual Funds Invested in MAXHEALTH

Mutual Funds Invested in MAXHEALTH

No mutual funds holding trends are available

Top 5 Mutual Funds holding Max Healthcare Institute Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
1.3263%1.38%0.80%23/78 (+12)
0.8441%2.46%0.76%22/33 (-1)
0.6316%0.80%-0.12%25/138 (0)

Compare 3-month MF holding change on Screener

MAXHEALTH Insider Trades & Bulk Stock Deals

MAXHEALTH Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing MAXHEALTH stock

smallcases containing MAXHEALTH stock

Looks like this stock is not in any smallcase yet.

MAXHEALTH Events

MAXHEALTH Events

MAXHEALTH Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

MAXHEALTH Dividend Trend

No dividend trend available

MAXHEALTH Upcoming Dividends

MAXHEALTH Upcoming Dividends

No upcoming dividends are available

MAXHEALTH Past Dividends

MAXHEALTH Past Dividends

Cash Dividend

Ex DateEx DateJul 4, 2025

Final
Final | Div/Share: ₹1.50

Dividend/Share

1.50

Ex DateEx Date

Jul 4, 2025

Cash Dividend

Ex DateEx DateAug 23, 2024

Final
Final | Div/Share: ₹1.50

Dividend/Share

1.50

Ex DateEx Date

Aug 23, 2024

Cash Dividend

Ex DateEx DateSep 8, 2023

Final
Final | Div/Share: ₹1.00

Dividend/Share

1.00

Ex DateEx Date

Sep 8, 2023

MAXHEALTH Stock News & Opinions

MAXHEALTH Stock News & Opinions

Corporate
Corporate
Board of Max Healthcare Institute recommends final dividend

Max Healthcare Institute announced that the Board of Directors of the Company at its meeting held on 21 May 2026, inter alia, have recommended the final dividend of Rs 2 per equity Share (i.e. 20%) , subject to the approval of the shareholders.

4 weeks agoCapital Market - Live
Earnings
Earnings
Max Healthcare Institute consolidated net profit rises 7.28% in the March 2026 quarter

Net profit of Max Healthcare Institute rose 7.28% to Rs 342.22 crore in the quarter ended March 2026 as against Rs 319.00 crore during the previous quarter ended March 2025. Sales rose 12.21% to Rs 2142.89 crore in the quarter ended March 2026 as against Rs 1909.74 crore during the previous quarter ended March 2025. For the full year,net profit rose 34.07% to Rs 1442.41 crore in the year ended March 2026 as against Rs 1075.88 crore during the previous year ended March 2025. Sales rose 19.14% to Rs 8373.45 crore in the year ended March 2026 as against Rs 7028.46 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales2142.891909.74 12 8373.457028.46 19 OPM %28.3026.79 -26.7926.30 - PBDT587.60503.33 17 2170.351839.42 18 PBT464.58402.50 15 1723.821480.00 16 NP342.22319.00 7 1442.411075.88 34 Powered by Capital Market - Live

4 weeks agoCapital Market - Live
Spotlight
Spotlight
Max Healthcare Institute reports 7% YoY rise in Q4 PAT

Revenue from operations rose 12.20% YoY to Rs 2,142.89 crore during the quarter. The company's network gross revenue stood at Rs 2,664 crore, registering a 10% YoY growth, primarily driven by higher occupied bed days (OBDs). International patient revenue increased 12% YoY to Rs 227 crore and contributed around 9% of hospital revenue. Network operating EBITDA came in at Rs 682 crore, up 8% YoY. EBITDA margin for the network stood at 26.8% compared with 27.2% in Q4 FY25 and 26.1% in Q3 FY26. The company said clinician costs increased nearly 230 basis points YoY and 120 basis points sequentially due to aggressive hiring of clinical talent to support future growth and ongoing capacity expansions. Overall EBITDA per bed stood at Rs 73.4 lakh compared with Rs 73.9 lakh in Q4 FY25 and Rs 71.3 lakh in Q3 FY26. Max Lab, the company's non-captive pathology business, reported revenue of Rs 52 crore during the quarter, reflecting growth of 14% YoY and 11% QoQ. The pathology network now operates across more than 60 cities and offers over 2,700 tests. Max@Home reported gross revenue of Rs 73 crore, up 30% YoY and 8% QoQ, driven by growth in physiotherapy, rehabilitation, nursing care, sample collection, and medicine delivery services. Network PAT stood at Rs 387 crore, compared with Rs 376 crore in Q4 FY25, registering growth of 3% YoY and 12% sequentially. Free cash flow from operations rose to Rs 581 crore in Q4 FY26 from Rs 422 crore in the year-ago quarter. During the quarter, the company deployed Rs 328 crore towards ongoing expansion plans and new unit upgrades. Net debt at the end of March 2026 stood at Rs 1,908 crore compared with Rs 2,166 crore at the end of December 2025. The company said nearly 20% additional brownfield capacity has been commissioned over the last six months, with another 10% capacity addition expected from the upcoming Gurugram facility later this year. A 400-bed brownfield tower at Max Smart Super Speciality Hospital was commissioned in April 2026. Currently, 156 beds have been handed over to operations, with the remaining beds expected to be progressively handed over during the next quarter. Additionally, a 160-bed brownfield tower at MSSH, Mohali has been fully commissioned and operationalized. Similarly, 116 beds out of the planned 280-bed brownfield tower at Nanavati Max have been operationalized, with the balance beds expected to become operational over the next three months. Max Healthcare also completed the acquisition of a 58.28% controlling stake in Kalinga Hospital on 18 May 2026, making it a subsidiary of the company. Kalinga Hospital operates a 250-bed facility spread across a prime 10-acre land parcel in the heart of Bhubaneswar, Odisha. Meanwhile, the board approved an investment of around Rs 1,400 crore for the construction of a 712-bed greenfield hospital at Shaheed Path in Lucknow. The facility is expected to be commissioned in FY30. Abhay Soi, chairman and managing director, Max Healthcare Institute, said, 'We are pleased to announce the phased commissioning and ramp-up of brownfield expansions across Mohali, Mumbai and Delhi, representing approximately 20% capacity addition. We also look forward to augmenting our capacity by another ~10% with the commissioning of the greenfield Gurgaon facility by the end of the year. We are also happy that the network has delivered its 22nd consecutive quarter of year-on-year growth, with revenue increasing by 10% and operating EBITDA grew by 8%. Further, we have completed the acquisition of a controlling stake in Kalinga Hospital, Bhubaneswar. The team has already begun integration and is working towards achieving significant operational upside. In parallel, work has commenced on the upgradation and expansion of the hospital, enabling us to extend high-quality healthcare services in a fast-growing region.' further, the company's board has recommended a final dividend of Rs 2 per equity share of face value Rs 10 each for FY26, subject to shareholders' approval at the forthcoming annual general meeting (AGM). If approved, the dividend will be paid or dispatched within 30 days from the conclusion of the AGM. Max Healthcare Institute (Max Healthcare) is one of India's largest healthcare organisations. The company operates 21 healthcare facilities (nearly 6,000 beds) with a significant presence in North India. In addition to the hospitals, Max Healthcare operates homecare and pathology businesses under brand names Max@Home and Max Lab, respectively. The scrip had added 1.42% to end at Rs 1091.55 on the BSE. Powered by Capital Market - Live

4 weeks agoCapital Market - Live
Corporate
Corporate
Max Healthcare Institute to table results

Max Healthcare Institute will hold a meeting of the Board of Directors of the Company on 21 May 2026.

1 month agoCapital Market - Live
Corporate
Corporate
Max Healthcare Institute allots 51,287 equity shares under ESOS

Max Healthcare Institute has allotted 51,287 equity shares under ESOS on 01 May 2026. With this allotment, the paid up equity share capital has increased to 97,32,43,789 equity shares of Rs 10 each.

1 month agoCapital Market - Live
Spotlight
Spotlight
Max Healthcare gains after deal to acquire over 58% stake in Bhubaneswar-based Kalinga Hospital

Under the agreement, MHIL shall acquire 58.4% stake in KHL at an equity value of Rs 300 crore. The 250 bed NABH accredited hospital is built on a 10-acre land parcel at Maitri Vihar, Bhubaneswar, a prime location in the heart of the city. Spread over 2.60 lakh square feet, the hospital provides multidisciplinary care across major specialties, including neurology, cardiology, orthopaedics, gastroenterology, renal sciences and oncology; backed by diagnostics and equipped with a 128-slice CT scanner, 1.5T MRI, and cath lab, etc. Bhubaneswar has a well-developed healthcare eco-system with large footprint of public, private hospitals and multiple medical colleges, positioning the city as a preferred healthcare provider for patients from across Odisha and neighbouring states of West Bengal, Jharkhand and Chhattisgarh. This acquisition will strengthen MHIL's network and expand its footprint in Eastern India. Abhay Soi, chairman and managing director, Max Healthcare Institute, said: 'Happy to announce our foray into Bhubaneswar, an extremely attractive market, through the acquisition of a very well located and reputable hospital with significant operational upside and brownfield potential.' Max Healthcare Institute is one of India's largest healthcare organizations. The company operates 20 healthcare facilities, with a significant presence in North India. In addition to the hospitals, Max Healthcare operates homecare and pathology businesses under brand names Max@Home and Max Lab, respectively. The company's consolidated net profit rose 26.01% to Rs 300.92 crore on a 10.66% increase in revenue to Rs 2,067.52 crore in Q3 FY26 over Q3 FY25.

2 months agoCapital Market - Live
Corporate
Corporate
Max Healthcare Institute approves acquisition of controlling stake in Kalinga Hospital, Bhubaneswar

The board of Max Healthcare Institute at its meeting held on 08 April 2026 has approved to enter into share purchase agreement (SPA) for acquisition of controlling stake (~58.39%) in Kalinga Hospital (KHL), which operates a 250 bedded Multi-Specialty Hospital by the name of 'Kalinga Hospital' in Bhubaneswar, Orissa. Further, the board has approved to provide loans up to Rs 100 crore to KHL towards cost of construction, renovation, upgradation, equipment etc. The Board has also approved issuance of corporate guarantee to Bank/ Financial Institution for re-financing of external commercial borrowings of existing promoter of KHL of $5 Mn (along with interest due thereon). Also, the board has approved the senior secured term loan of amount up to Rs 300 crore in the form of external commercial borrowings for financing the acquisition.

2 months agoCapital Market - Live
Corporate
Corporate
Max Healthcare Institute allots 57,461 equity shares under ESOP

Max Healthcare Institute has allotted 57,461 equity shares under ESOP on 01 April 2026. With this allotment, the paid up equity share capital has increased to Rs 973,19,25,020 comprising of 97,31,92,502 equity shares of Rs 10 each.

2 months agoCapital Market - Live
Corporate
Corporate
Max Healthcare Institute allots 42,266 equity shares under ESOS

Max Healthcare Institute has allotted 42,266 equity shares under ESOS on 17 March 2026. With this allotment, the paid up equity share capital has increased to 97,31,35,041 equity shares of Rs 10 each. Powered by Capital Market - Live

3 months agoCapital Market - Live
Earnings
Earnings
Max Healthcare Institute consolidated net profit rises 26.01% in the December 2025 quarter

Net profit of Max Healthcare Institute rose 26.01% to Rs 300.92 crore in the quarter ended December 2025 as against Rs 238.80 crore during the previous quarter ended December 2024. Sales rose 10.66% to Rs 2067.52 crore in the quarter ended December 2025 as against Rs 1868.31 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales2067.521868.31 11 OPM %26.0426.72 - PBDT524.05480.04 9 PBT412.78382.50 8 NP300.92238.80 26 Powered by Capital Market - Live

4 months agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. What is the share price of Max Healthcare Institute Ltd (MAXHEALTH) today?

    The share price of MAXHEALTH as on 19th June 2026 is ₹1094.75. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Max Healthcare Institute Ltd (MAXHEALTH) share?

    The past returns of Max Healthcare Institute Ltd (MAXHEALTH) share are
    • Past 1 week: 7.54%
    • Past 1 month: 3.12%
    • Past 3 months: 14.86%
    • Past 6 months: 1.76%
    • Past 1 year: -5.87%
    • Past 3 years: 81.96%
    • Past 5 years: 344.30%

  3. What are the peers or stocks similar to Max Healthcare Institute Ltd (MAXHEALTH)?
  4. What is the dividend yield % of Max Healthcare Institute Ltd (MAXHEALTH) share?

    The current dividend yield of Max Healthcare Institute Ltd (MAXHEALTH) is 0.18.

  5. What is the market cap of Max Healthcare Institute Ltd (MAXHEALTH) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Max Healthcare Institute Ltd (MAXHEALTH) is ₹106545.86 Cr as of 19th June 2026.

  6. What is the 52 week high and low of Max Healthcare Institute Ltd (MAXHEALTH) share?

    The 52-week high of Max Healthcare Institute Ltd (MAXHEALTH) is ₹1314.30 and the 52-week low is ₹903.

  7. What is the PE and PB ratio of Max Healthcare Institute Ltd (MAXHEALTH) stock?

    The P/E (price-to-earnings) ratio of Max Healthcare Institute Ltd (MAXHEALTH) is 73.87. The P/B (price-to-book) ratio is 11.36.

  8. Which sector does Max Healthcare Institute Ltd (MAXHEALTH) belong to?

    Max Healthcare Institute Ltd (MAXHEALTH) belongs to the Health Care sector & Hospitals & Diagnostic Centres sub-sector.

  9. How to buy Max Healthcare Institute Ltd (MAXHEALTH) shares?

    You can directly buy Max Healthcare Institute Ltd (MAXHEALTH) shares on Tickertape. Simply sign up, connect your demat account and place your order.